Clinical trialsCompany release

Monte Rosa plans three Phase 2 trials of NEK7 degrader MRT-8102 after Phase 1 data

🇺🇸 Monte Rosa Therapeutics, Inc. (GLUE) · Thu 05 Nov 2026

The US biotech reported Q3 2026 results, with Novartis milestones of $87.5 million and cash of $582.6 million expected to fund operations into 2029.

Monte Rosa Therapeutics reported its third-quarter 2026 results on 5 November, alongside an update on its clinical pipeline. The company said it plans to move its NEK7 degrader, MRT-8102, into three Phase 2 trials following Phase 1 data.

The GFORCE-1 Phase 1 study enrolled 108 obese subjects at elevated cardiovascular risk. According to the company, MRT-8102 achieved NEK7 degradation of roughly 80% to 90%, and adverse event rates were similar to those seen with placebo.

Phase 2 development is scheduled to begin with a gout trial in the fourth quarter of 2026. Trials in coronary artery disease and hidradenitis suppurativa are planned for the first half of 2027.

On the partnering side, Novartis has started two Phase 2a/b trials of MRT-6160 in Sjögren's disease and psoriatic arthritis. The two trial starts triggered milestone payments totalling $87.5 million for Monte Rosa.

The company reported cash of $582.6 million at the end of the quarter, which it expects to fund operations into 2029.

What it means for your team

  • The Phase 1 safety signal, with adverse events similar to placebo, will be tested in larger Phase 2 populations across gout, coronary artery disease and hidradenitis suppurativa, so safety databases will grow substantially.
  • Regulatory teams tracking the NEK7 degrader class should watch for Phase 2 protocol start-ups, beginning with gout in Q4 2026.
  • Novartis's two Phase 2a/b starts for MRT-6160 show the partnered programme moving into later-stage testing in Sjögren's disease and psoriatic arthritis.

Company's press release (SEC filing): Monte Rosa Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Monte Rosa Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →